Cuneo Gilbert Flannery & LaDuca, LLP Partner Christian Hudson was featured in a recent Law360 article discussing the latest development in the In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724) pending in the U.S. District Court for the Eastern District of Pennsylvania.
The motion, filed on behalf of a proposed nationwide class of thousands of pharmacies, seeks certification for indirect reseller plaintiffs who purchased the cholesterol medication pravastatin between May 1, 2013, and December 31, 2018. The plaintiffs allege that Glenmark Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., and Zydus Pharmaceuticals (USA) Inc. entered into a anticompetitive agreement to fix prices for pravastatin, resulting in overcharges that reached as high as 1,000%.
According to the motion, the alleged collusion forced pharmacies—particularly small and rural businesses—to absorb substantial financial losses, contributing to closures across the country.
Hudson, who serves as lead counsel for the indirect reseller plaintiffs, emphasized the broader importance of the case, stating:
“For nearly a decade, pharmacies have led the fight to hold generic drug manufacturers accountable for allocating markets and coordinating price increases that hurt small businesses and consumers alike. Our motion seeks class certification so these pharmacies can pursue justice collectively and recover damages from years of unlawful overcharges.”
Cuneo Gilbert Flannery & LaDuca, LLP, along with co-counsel, continues to represent the interests of pharmacies and other purchasers affected by alleged anticompetitive conduct in the generic pharmaceutical industry.
Read the full article on Law360: https://www.law360.com/articles/2406763/pharmacies-seek-cert-in-cholesterol-drug-price-fixing-mdl?te_pk=5c8d731e-c6e6-4d16-904d-c7995ab46496